Sato Pharmaceutical,
Evolving Healthcare Innovation to
Achieve Sustainable Growth
As Japan’s population rapidly ages and the birthrate continues to decline, serious measures will be needed to maintain the balance of supply and demand for medical and long-term care services in the country and the sustainability of Japan’s social security system as we head toward 2040, the peak year of the population’s aging.
The Japanese government has identified several important areas for action beyond addressing the falling birthrate and reforming social security. These include DX promotion and utilizing information and communication technology, task shifting among healthcare professionals, creating an environment that can take advantage of the potential workforce that includes women and seniors, and extending the length of time that elderly people can maintain their health.
The government’s Basic Policies for Economic and Fiscal Management and Reform 2023 even mentions the expansion of OTC drugs to promote self-medication.
To meet these social needs, our mainstay healthcare business is focused on developing high-added-value products such as Switch OTC drugs and supplying high-quality products.
For our flagship brands, we appoint leaders in various fields to be our brand ambassadors and help us disseminate information through a variety of media.
In the pharmaceutical business, we offer highly original products primarily in the field of dermatology, and conduct detailed information campaigns using digital media. In new drug creation and development, we have been working with both domestic and foreign companies,
universities and research institutions to improve our research on the synthesis of new compounds with high utility and enhance our research facilities.
In our global business, our six bases in Asia, North America and Europe offer products and conduct marketing tailored to the needs of each region. We have started to expand our pharmaceuticals globally, including the expansion of our topical onychomycosis treatment,
LUCONAC, into Asia, using Singapore as a base, and are developing antifungal agents in North America.
In our CSR pursuits, we continue to work toward the SDGs by fostering an atmosphere that supports self-care and self-medication, developing human resources that are in line with societal demands, and protecting the environment, primarily at our production sites. These initiatives are carried out through the OTC Self-Medication Promotion Foundation and the Sato Scholarship Foundation.
The Company celebrated its 100th anniversary in 2015, and under our corporate philosophy of promoting healthcare innovation, we will continue to contribute to consumer health through our health-related businesses centered around OTC drugs and pharmaceuticals.
Thank you very much; we hope to continue to draw on your invaluable advice and support.
Seiichi Sato
President and CEO
